⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of CenExel Clinical Research and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
CenExel Clinical Research
↗Salt Lake City, USA
CenExel is a leading, nationwide clinical research site network that partners with pharmaceutical and biotechnology sponsors and CROs to conduct clinical trials. The company operates a network of Centers of Excellence, providing deep scientific expertise, patient recruitment, and infrastructure to accelerate the development of new therapies across various therapeutic areas.
With over 40 years of collective experience, CenExel focuses on delivering high-quality data, operational efficiency, and exceptional patient engagement. The company has expanded its capabilities significantly, investing in purpose-built facilities, inpatient/outpatient capacities, and advanced pharmacy and laboratory infrastructure to support complex research challenges.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1001-5000
Revenue:$100M-$500M
Founded:2018
Ownership:private
Status:operating
FUNDING
Stage:Private Equity-Backed
Total Raised:$7.37M
Investors:BayPine, Biospring Partners
PIPELINE
Active Trials:60
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:CenExel ACT, ACMR, AMRI, CBH, CIT, CNR, CNS, FCR, HRI, iResearch, JBR, RCA
Key Partnerships:Pharmaceutical and Biotech Sponsors, Contract Research Organizations (CROs)
COMPETITION
Position:Leader
Competitors:ProRelix Research, Proxima, Novum Pharmaceutical Research Services, Alliance Clinical Network, Clinvest Research, Circuit Clinical
LEADERSHIP
Key Executives:
Ryan Brooks - CEO
LINKS
Website:cenexel.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with CenExel Clinical Research. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.